TABLE 4.
In vitro activity of cefepime-taniborbactam and comparator agents against 1,110 isolates of P. aeruginosa with molecularly identified β-lactamase genotypes
| Genotype (no. of isolates; % of total molecularly characterized isolates) | Antimicrobial agent | MIC (μg/mL) |
MIC interpretation |
||||
|---|---|---|---|---|---|---|---|
| MIC50 | MIC90 | MIC range | Susceptible (%) | Intermediate (%) | Resistant (%) | ||
| Carbapenemase positive (249; 22.4)a | Cefepime-taniborbactamb | 8 | >32 | 1 to >32 | 71.5 | NAc | 28.5 |
| Ceftazidime-avibactam | >16 | >16 | 2 to >16 | 14.9 | NA | 85.1 | |
| Ceftolozane-tazobactam | >16 | >16 | 1 to >16 | 1.2 | 2.4 | 96.4 | |
| Meropenem-vaborbactam | >16 | >16 | 1 to >16 | 7.6 | NA | 92.4 | |
| Piperacillin-tazobactam | 64 | >128 | 2 to >128 | 3.2 | 49.4 | 47.4 | |
| MBL positive (209; 18.8)d | Cefepime-taniborbactam | 8 | >32 | 1 to >32 | 66.5 | NA | 33.5 |
| Ceftazidime-avibactam | >16 | >16 | 4 to >16 | 2.9 | NA | 97.1 | |
| Ceftolozane-tazobactam | >16 | >16 | 1 to >16 | 1.0 | 0 | 99.0 | |
| Meropenem-vaborbactam | >16 | >16 | 4 to >16 | 7.7 | NA | 92.3 | |
| Piperacillin-tazobactam | 64 | >128 | 2 to >128 | 3.4 | 49.3 | 47.4 | |
| VIM positive (159; 14.3)e | Cefepime-taniborbactam | 8 | 32 | 1 to >32 | 87.4 | NA | 12.6 |
| Ceftazidime-avibactam | >16 | >16 | 4 to >16 | 3.8 | NA | 96.2 | |
| Ceftolozane-tazobactam | >16 | >16 | 1 to >16 | 1.3 | 0 | 98.7 | |
| Meropenem-vaborbactam | >16 | >16 | 4 to >16 | 6.9 | NA | 93.1 | |
| Piperacillin-tazobactam | 64 | >128 | 16 to >128 | 2.5 | 56.6 | 40.9 | |
| GES positive (51; 4.6)f | Cefepime-taniborbactam | 8 | 16 | 1 to >32 | 98.0 | NA | 2.0 |
| Ceftazidime-avibactam | 8 | >16 | 2 to >16 | 54.9 | NA | 45.1 | |
| Ceftolozane-tazobactam | >16 | >16 | 8 to >16 | 0 | 11.8 | 88.2 | |
| Meropenem-vaborbactam | >16 | >16 | 0.25 to >16 | 21.6 | NA | 78.4 | |
| Piperacillin-tazobactam | 64 | >128 | 16 to >128 | 5.9 | 54.9 | 39.24 | |
| VEB positive (21; 1.9) | Cefepime-taniborbactam | 8 | 8 | 4 to 8 | 100 | NA | 0 |
| Ceftazidime-avibactam | >16 | >16 | 16 to >16 | 0 | 100 | ||
| Ceftolozane-tazobactam | >16 | >16 | >16 | 0 | 0 | 100 | |
| Meropenem-vaborbactam | >16 | >16 | 16 to >16 | 0 | 100 | ||
| Piperacillin-tazobactam | 128 | >128 | 32 to >128 | 0 | 42.9 | 57.1 | |
Includes isolates harboring GES-2, GES-5, GES-6, and GES-20 (variants with reported carbapenemase activity).
For comparative purposes only, percent susceptible and percent resistant for cefepime-taniborbactam correspond to the percentage of isolates inhibited at ≤16 μg/mL and ≥32 μg/mL, respectively.
NA, not applicable.
Includes isolates harboring VIM (n = 159), IMP (n = 28), and NDM (n = 16). Two isolates cocarried IMP and DIM, three isolates cocarried IMP and VIM, and one isolate cocarried NDM and DIM.
Isolates could also possess serine carbapenemases, ESBLs, AmpCs, and/or OSBLs, but no other MBLs.
The 51 GES-positive isolates comprised 33 isolates with a GES carbapenemase and 18 isolates with a GES ESBL.